131 related articles for article (PubMed ID: 31638158)
1. A look back: the quest for thrombosis in heart failure continues after COMMANDER HF.
Filippatos G; Farmakis D
Cardiovasc Res; 2019 Nov; 115(13):e140-e142. PubMed ID: 31638158
[No Abstract] [Full Text] [Related]
2. Successful COMPASS, Disappointing COMMANDER HF, What Have We Learned From These Two Trials?
He Y; Hu X; Zhou S
J Cardiovasc Pharmacol; 2019 Oct; 74(4):306-307. PubMed ID: 31356557
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban in peripheral artery disease: The new kid on the block?
Hussain MA; Verma S; Al-Omran M
J Vasc Surg; 2018 Mar; 67(3):985-986. PubMed ID: 29477208
[No Abstract] [Full Text] [Related]
4. Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
Med Lett Drugs Ther; 2018 Dec; 60(1561):196-197. PubMed ID: 30653475
[No Abstract] [Full Text] [Related]
5. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
Mehra MR; Vaduganathan M; Fu M; Ferreira JP; Anker SD; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; Spiro TE; Deng H; Zannad F; Greenberg B
Eur Heart J; 2019 Nov; 40(44):3593-3602. PubMed ID: 31461239
[TBL] [Abstract][Full Text] [Related]
6. The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.
Camm AJ
Thromb Haemost; 2018 May; 118(S 01):S2-S11. PubMed ID: 29566415
[TBL] [Abstract][Full Text] [Related]
7. Triple therapy: worth the risk?
Wernly B; Lichtenauer M; Hoppe UC; Lauten A; Navarese EP; Jung C
Minerva Med; 2018 Oct; 109(5):403-405. PubMed ID: 30338683
[No Abstract] [Full Text] [Related]
8. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Zannad F; Anker SD; Byra WM; Cleland JGF; Fu M; Gheorghiade M; Lam CSP; Mehra MR; Neaton JD; Nessel CC; Spiro TE; van Veldhuisen DJ; Greenberg B;
N Engl J Med; 2018 Oct; 379(14):1332-1342. PubMed ID: 30146935
[TBL] [Abstract][Full Text] [Related]
9. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
Boden WE; Bhatt DL
Circulation; 2018 Aug; 138(9):858-860. PubMed ID: 30354448
[No Abstract] [Full Text] [Related]
10. Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.
Patrono C
Cardiovasc Res; 2017 Dec; 113(14):e61-e63. PubMed ID: 29186439
[No Abstract] [Full Text] [Related]
11. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Greenberg B; Neaton JD; Anker SD; Byra WM; Cleland JGF; Deng H; Fu M; La Police DA; Lam CSP; Mehra MR; Nessel CC; Spiro TE; van Veldhuisen DJ; Vanden Boom CM; Zannad F
JAMA Cardiol; 2019 Jun; 4(6):515-523. PubMed ID: 31017637
[TBL] [Abstract][Full Text] [Related]
12. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
Carnicelli AP; De Caterina R; Halperin JL; Renda G; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman E; Giugliano RP;
Circulation; 2017 Mar; 135(13):1273-1275. PubMed ID: 28209729
[No Abstract] [Full Text] [Related]
13. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
[TBL] [Abstract][Full Text] [Related]
14. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
[TBL] [Abstract][Full Text] [Related]
15. The impact of low-dose anticoagulation therapy on peripheral artery disease: insights from the VOYAGER trial.
Fukaya E; Leeper NJ
Cardiovasc Res; 2020 Oct; 116(12):e156-e158. PubMed ID: 32980875
[No Abstract] [Full Text] [Related]
16. Rivaroxaban with or without aspirin for prevention of cardiovascular disease.
Kruger PC; Eikelboom JW; Yusuf S
Coron Artery Dis; 2018 Aug; 29(5):361-365. PubMed ID: 29346127
[No Abstract] [Full Text] [Related]
17. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
[TBL] [Abstract][Full Text] [Related]
18. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.
Zannad F; Greenberg B; Cleland JG; Gheorghiade M; van Veldhuisen DJ; Mehra MR; Anker SD; Byra WM; Fu M; Mills RM
Eur J Heart Fail; 2015 Jul; 17(7):735-42. PubMed ID: 25919061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
